PURPOSE: Signal transducer and activator of transcription 5a/b (Stat5a/b) is the key mediator of prolactin effects in prostate cancer cells via activation of Janus-activated kinase 2. Prolactin is a locally produced growth factor in human prostate cancer. Prolactin protein expression and constitutive activation of Stat5a/b are associated with high histologic grade of clinical prostate cancer. Moreover, activation of Stat5a/b in primary prostate cancer predicts early disease recurrence. Here, we inhibited Stat5a/b by several different methodologic approaches. Our goal was to establish a proof of principle that Stat5a/b is critical for prostate cancer cell viability in vitro and for prostate tumor growth in vivo. EXPERIMENTAL DESIGN: We inhibited Stat5a/b protein expression by antisense oligonucleotides or RNA interference and transcriptional activity of Stat5a/b by adenoviral expression of a dominant-negative mutant of Stat5a/b in prostate cancer cells in culture. Moreover, Stat5a/b activity was suppressed in human prostate cancer xenograft tumors in nude mice. Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels was shown by antisense suppression of Stat5a/b protein expression followed by Western blotting. RESULTS AND CONCLUSIONS: We show here that inhibition of Stat5a/b by antisense oligonucleotides, RNA interference, or adenoviral expression of dominant-negative Stat5a/b effectively kills prostate cancer cells. Moreover, we show that Stat5a/b is critical for human prostate cancer xenograft growth in nude mice. The effects of Stat5a/b on the viability of prostate cancer cells involve Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels but not the expression or activation of Stat3. This work establishes Stat5a/b as a therapeutic target protein for prostate cancer. Pharmacologic inhibition of Stat5a/b in prostate cancer can be achieved by small-molecule inhibitors of transactivation, dimerization, or DNA binding of Stat5a/b.
PURPOSE:Signal transducer and activator of transcription 5a/b (Stat5a/b) is the key mediator of prolactin effects in prostate cancer cells via activation of Janus-activated kinase 2. Prolactin is a locally produced growth factor in humanprostate cancer. Prolactin protein expression and constitutive activation of Stat5a/b are associated with high histologic grade of clinical prostate cancer. Moreover, activation of Stat5a/b in primary prostate cancer predicts early disease recurrence. Here, we inhibited Stat5a/b by several different methodologic approaches. Our goal was to establish a proof of principle that Stat5a/b is critical for prostate cancer cell viability in vitro and for prostate tumor growth in vivo. EXPERIMENTAL DESIGN: We inhibited Stat5a/b protein expression by antisense oligonucleotides or RNA interference and transcriptional activity of Stat5a/b by adenoviral expression of a dominant-negative mutant of Stat5a/b in prostate cancer cells in culture. Moreover, Stat5a/b activity was suppressed in humanprostate cancer xenograft tumors in nude mice. Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels was shown by antisense suppression of Stat5a/b protein expression followed by Western blotting. RESULTS AND CONCLUSIONS: We show here that inhibition of Stat5a/b by antisense oligonucleotides, RNA interference, or adenoviral expression of dominant-negative Stat5a/b effectively kills prostate cancer cells. Moreover, we show that Stat5a/b is critical for humanprostate cancer xenograft growth in nude mice. The effects of Stat5a/b on the viability of prostate cancer cells involve Stat5a/b regulation of Bcl-X(L) and cyclin D1 protein levels but not the expression or activation of Stat3. This work establishes Stat5a/b as a therapeutic target protein for prostate cancer. Pharmacologic inhibition of Stat5a/b in prostate cancer can be achieved by small-molecule inhibitors of transactivation, dimerization, or DNA binding of Stat5a/b.
Authors: Bassem R Haddad; Andrew Erickson; Vindhya Udhane; Peter S LaViolette; Janice D Rone; Markku A Kallajoki; William A See; Antti Rannikko; Tuomas Mirtti; Marja T Nevalainen Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-07-10 Impact factor: 4.254
Authors: Tuomas Mirtti; Benjamin E Leiby; Junaid Abdulghani; Elina Aaltonen; Miia Pavela; Anita Mamtani; Kalle Alanen; Lars Egevad; Torvald Granfors; Andreas Josefsson; Par Stattin; Anders Bergh; Marja T Nevalainen Journal: Hum Pathol Date: 2012-09-29 Impact factor: 3.466
Authors: Neville N C Tam; Carol Y Y Szeto; Johannes M Freudenberg; Amy N Fullenkamp; Mario Medvedovic; Shuk-Mei Ho Journal: Mol Endocrinol Date: 2010-09-22
Authors: Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen Journal: Mol Cancer Ther Date: 2019-09-23 Impact factor: 6.261
Authors: Ayush Dagvadorj; Shyh-Han Tan; Zhiyong Liao; Luciane R Cavalli; Bassem R Haddad; Marja T Nevalainen Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen Journal: Mol Cancer Ther Date: 2014-02-27 Impact factor: 6.261
Authors: Jill Gallaher; Leah M Cook; Shilpa Gupta; Arturo Araujo; Jasreman Dhillon; Jong Y Park; Jacob G Scott; Julio Pow-Sang; David Basanta; Conor C Lynch Journal: Clin Exp Metastasis Date: 2014-08-31 Impact factor: 5.150